Effect of analytical error on the assessment of cardiac risk by the high-sensitivity C-reactive protein and lipid screening model

Clinical Chemistry

Volumn 48, Issue 11, 2002, Pages 1955-1962

  Middleton, John ^a  

^a BECKMAN COULTER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; DEXTRAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ANALYTICAL ERROR; ARTICLE; ASSAY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC ACCURACY; HUMAN; LABORATORY TEST; LIPID ANALYSIS; MEDICAL DECISION MAKING; MONTE CARLO METHOD; RISK ASSESSMENT;

EID: 0036840485     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.11.1955     Document Type: Article

References (16)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [Special Communication]. JAMA 2001;285:248697.
2. Rohde LEP, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999;84:1018-22.
3. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med 2000;342:836-43.
4. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
5. Rifai N, Ridker PM. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem 2001;47:403-11.
6. Cooper GR, Smith SJ, Myers GL, Sampson EJ, Magid E. Estimating and minimizing effects of biologic sources of variation by relative range when measuring the mean of serum lipids and lipoproteins. Clin Chem 1994;40:227-32.
7. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5.
8. Cambell B, Badrick T, Flatman R, Kanowski D. Limited clinical utility of high-sensitivity plasma C-reactive protein assays [Comment]. Ann Clin Biochem 2002;39:85-8.
9. Boyd JC, Bruns DE. Quality specifications for glucose meters: Assessment by simulation modeling of errors in insulin dose. Clin Chem 2001;47:1329-31.
10. Bennett ST, Eckfeldt JH, Belcher JD, Connelly DP. Certification of cholesterol measurements by the National Reference Method Laboratory Network with routine clinical specimens: Effects of network laboratory bias and imprecision. Clin Chem 1992;38:651-7.
11. Box GEP, Muller ME. A note on the generation of random normal deviates. Ann Math Stat 1958;29:610-1.
12. Krouwer JS. Estimating total analytical error and its sources. Arch Pathol Lab Med 1992;116:726-31.
13. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Part 2. Clin Chem 2001;47:418-25.
14. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Clin Chem 2000;46:461-8.
15. Ku HH. Notes on the use of propagation of error formulas. J Res Natl Bur Stand Sect C 1966;70C:263-73.
16. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening [Opinion]. Clin Chem 2001;47:28-30.